MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DR. REDDYS LAB - CIPLA
DR. REDDYS LAB vs CIPLA - Comparison Results
DR. REDDYS LAB Change
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More
CIPLA 
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Current Valuations
| DR. REDDYS LAB | CIPLA | DR. REDDYS LAB/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.5 | 28.0 | 80.3% | View Chart |
| P/BV | x | 3.1 | 3.0 | 103.4% | View Chart |
| Dividend Yield | % | 0.8 | 0.6 | 134.8% |
Financials
 DR. REDDYS LAB  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. REDDYS LAB Mar-19 |
CIPLA Mar-18 |
DR. REDDYS LAB/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 2,875 | 663 | 433.6% | |
| Low | Rs | 1,888 | 479 | 394.2% | |
| Sales per share (Unadj.) | Rs | 930.2 | 189.0 | 492.1% | |
| Earnings per share (Unadj.) | Rs | 117.4 | 17.6 | 667.4% | |
| Cash flow per share (Unadj.) | Rs | 185.8 | 34.0 | 545.9% | |
| Dividends per share (Unadj.) | Rs | 20.00 | 3.00 | 666.7% | |
| Dividend yield (eoy) | % | 0.8 | 0.5 | 159.8% | |
| Book value per share (Unadj.) | Rs | 844.4 | 176.7 | 477.8% | |
| Shares outstanding (eoy) | m | 166.07 | 805.12 | 20.6% | |
| Bonus/Rights/Conversions | ESOP | ESOP | - | ||
| Price / Sales ratio | x | 2.6 | 3.0 | 84.8% | |
| Avg P/E ratio | x | 20.3 | 32.5 | 62.5% | |
| P/CF ratio (eoy) | x | 12.8 | 16.8 | 76.4% | |
| Price / Book Value ratio | x | 2.8 | 3.2 | 87.3% | |
| Dividend payout | % | 17.0 | 17.1 | 99.9% | |
| Avg Mkt Cap | Rs m | 395,496 | 459,724 | 86.0% | |
| No. of employees | `000 | 22.0 | 23.6 | 93.0% | |
| Total wages/salary | Rs m | 33,562 | 26,901 | 124.8% | |
| Avg. sales/employee | Rs Th | 7,032.8 | 6,446.1 | 109.1% | |
| Avg. wages/employee | Rs Th | 1,527.9 | 1,139.4 | 134.1% | |
| Avg. net profit/employee | Rs Th | 887.7 | 600.0 | 148.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 154,482 | 152,193 | 101.5% | |
| Other income | Rs m | 3,375 | 3,577 | 94.4% | |
| Total revenues | Rs m | 157,857 | 155,769 | 101.3% | |
| Gross profit | Rs m | 31,782 | 28,264 | 112.4% | |
| Depreciation | Rs m | 11,348 | 13,228 | 85.8% | |
| Interest | Rs m | 889 | 1,142 | 77.8% | |
| Profit before tax | Rs m | 22,920 | 17,470 | 131.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 438 | -28 | -1,575.5% | |
| Extraordinary Inc (Exp) | Rs m | 0 | -775 | 0.0% | |
| Tax | Rs m | 3,858 | 2,501 | 154.3% | |
| Profit after tax | Rs m | 19,500 | 14,166 | 137.7% | |
| Gross profit margin | % | 20.6 | 18.6 | 110.8% | |
| Effective tax rate | % | 16.8 | 14.3 | 117.6% | |
| Net profit margin | % | 12.6 | 9.3 | 135.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 111,101 | 108,141 | 102.7% | |
| Current liabilities | Rs m | 58,973 | 38,322 | 153.9% | |
| Net working cap to sales | % | 33.7 | 45.9 | 73.6% | |
| Current ratio | x | 1.9 | 2.8 | 66.8% | |
| Inventory Days | Days | 79 | 97 | 81.8% | |
| Debtors Days | Days | 94 | 74 | 126.6% | |
| Net fixed assets | Rs m | 101,245 | 109,411 | 92.5% | |
| Share capital | Rs m | 830 | 1,610 | 51.5% | |
| "Free" reserves | Rs m | 139,406 | 140,682 | 99.1% | |
| Net worth | Rs m | 140,236 | 142,292 | 98.6% | |
| Long term debt | Rs m | 22,000 | 36,621 | 60.1% | |
| Total assets | Rs m | 224,656 | 228,606 | 98.3% | |
| Interest coverage | x | 26.8 | 16.3 | 164.4% | |
| Debt to equity ratio | x | 0.2 | 0.3 | 61.0% | |
| Sales to assets ratio | x | 0.7 | 0.7 | 103.3% | |
| Return on assets | % | 9.1 | 6.7 | 135.5% | |
| Return on equity | % | 13.9 | 10.0 | 139.7% | |
| Return on capital | % | 14.9 | 10.0 | 150.1% | |
| Exports to sales | % | 0 | 32.8 | 0.0% | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | 49,883 | 0.0% | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 88,673 | 51,691 | 171.5% | |
| Fx outflow | Rs m | 19,104 | 21,033 | 90.8% | |
| Net fx | Rs m | 69,569 | 30,658 | 226.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 28,704 | 14,628 | 196.2% | |
| From Investments | Rs m | -7,727 | -8,540 | 90.5% | |
| From Financial Activity | Rs m | -21,326 | -3,855 | 553.2% | |
| Net Cashflow | Rs m | -314 | 2,431 | -12.9% | |
Share Holding
| Indian Promoters | % | 25.5 | 16.0 | 159.4% | |
| Foreign collaborators | % | 0.0 | 20.8 | - | |
| Indian inst/Mut Fund | % | 5.4 | 12.2 | 44.3% | |
| FIIs | % | 35.3 | 23.7 | 148.9% | |
| ADR/GDR | % | 18.5 | 1.1 | 1,681.8% | |
| Free float | % | 15.3 | 26.2 | 58.4% | |
| Shareholders | 75,885 | 161,166 | 47.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: ALKEM LABORATORIES PLETHICO PHARMA WOCKHARDT TORRENT PHARMA FRESENIUS KABI ONCO.
Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Flat; Energy and Automobiles Stocks Drag(09:30 am)
Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.9% while the Hang Seng is up 0.2%.
Related Views on News
CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)
May 24, 2019 | Updated on May 24, 2019For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.
DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMost Popular
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)
Jul 15, 2019While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.
Here's What to Do with Falling Small Cap Stocks(Profit Hunter)
Jul 10, 2019There are some great buying opportunities in the market right now - and the small cap space is your best bet.
7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)
Jul 18, 2019Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
More|
| |
DR. REDDYS LAB SHARE PRICE
Jul 23, 2019 10:19 AM
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB 5-YR ANALYSIS
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.